We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $21.7B
1-Year Est. Return 79.24%
This Fund
S&P 500
This Quarter Est. Return
-0.07%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$19.1B
AUM Growth
-$4.04B
Cap. Flow
-$3.24B
Cap. Flow %
-16.98%
Top 10 Hldgs %
50.33%
Holding
204
New
48
Increased
30
Reduced
30
Closed
31

Top Buys

Rank Stock Value
1
EA
Electronic Arts
EA
+$492M
2
AVGO icon
Broadcom
AVGO
+$292M
3
KKR icon
KKR & Co
KKR
+$280M
4
ROIV icon
Roivant Sciences
ROIV
+$248M
5
MA icon
Mastercard
MA
+$138M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$650M
2
CYBR
CyberArk
CYBR
+$470M
3
CRM icon
Salesforce
CRM
+$334M
4
NDAQ icon
Nasdaq
NDAQ
+$290M
5
RNAM
Avidity Biosciences
RNAM
+$233M

Sector Composition

Rank Sector Weight
1 Healthcare 46.53%
2 Communication Services 11.31%
3 Financials 11.23%
4 Technology 10.28%
5 Consumer Discretionary 4.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDTX
176
DELISTED
Cidara Therapeutics
CDTX
– –
-382,800
Closed -$84.6M
CRM icon
177
Salesforce
CRM
$161B
– –
-1,261,177
Closed -$334M
CYBR
178
DELISTED
CyberArk
CYBR
– –
-1,053,040
Closed -$470M
DOCS icon
179
Doximity
DOCS
$4.42B
– –
-311,000
Closed -$13.8M
EDU icon
180
New Oriental
EDU
$8.36B
– –
-196,000
Closed -$10.8M
ESTA icon
181
Establishment Labs
ESTA
$2.37B
– –
-3,000
Closed -$219K
EXAS
182
DELISTED
Exact Sciences
EXAS
– –
-6,405,000
Closed -$650M
GPCR icon
183
Structure Therapeutics
GPCR
$3.87B
– –
-454,000
Closed -$31.6M
HYG icon
184
PUT
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$17.9B
– –
-8,000,000
Closed -$645M
IBIT icon
185
iShares Bitcoin Trust
IBIT
$46.8B
– –
-2,137,100
Closed -$106M
ICLR icon
186
Icon
ICLR
$12.6B
– –
-1,200
Closed -$219K
INSM icon
187
CALL
Insmed
INSM
$27B
– –
-250,000
Closed -$43.5M
INSM icon
188
Insmed
INSM
$27B
– –
-3,000
Closed -$522K
LLY icon
189
PUT
Eli Lilly
LLY
$1.05T
– –
-375,000
Closed -$403M
MLYS icon
190
Mineralys Therapeutics
MLYS
$2.27B
– –
-823,296
Closed -$29.9M
NDAQ icon
191
Nasdaq
NDAQ
$54.2B
– –
-2,989,213
Closed -$290M
NYT icon
192
New York Times
NYT
$10.4B
– –
-3,280,678
Closed -$228M
RNAM
193
DELISTED
Avidity Biosciences
RNAM
– –
-3,233,000
Closed -$233M
RSP icon
194
PUT
Invesco S&P 500 Equal Weight ETF
RSP
$100B
– –
-3,600,000
Closed -$690M
SLNO
195
DELISTED
Soleno Therapeutics
SLNO
– –
-5,000
Closed -$232K
TRU icon
196
TransUnion
TRU
$15.4B
– –
-675,000
Closed -$57.9M
VSTM icon
197
Verastem
VSTM
$596M
– –
-2,000,000
Closed -$15.4M
DAY
198
DELISTED
Dayforce
DAY
– –
-2,925,000
Closed -$202M
ETH
199
Grayscale Ethereum Staking Mini ETF Shares
ETH
$1.72B
– –
-228,340
Closed -$6.41M
ETHA
200
iShares Ethereum Trust ETF
ETHA
$5.54B
– –
-1,481,001
Closed -$33.2M
5 6 7
8
9

Similar funds

VARA
Value Aligned Research Advisors Princeton, New Jersey $20.7B AUM 292.88% 1-Year Est. Return
Tiger Global Management
Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
NAM
Nissay Asset Management Tokyo, Japan $18.9B AUM 27.21% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return

Farallon Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Farallon Capital Management held 204 positions worth $19.1B, down 17% from $23.1B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Farallon Capital Management withdrew a net $3.24B in Q1 2026, closing 31 positions and reducing 30 holdings. Its most notable exit was Exact Sciences, an estimated $650M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 41% a quarter earlier, followed by Communication Services and Financials.

Against the trend, Farallon Capital Management opened a new position in Dianthus Therapeutics worth $70.2M.

  • Farallon Capital Management's largest Q1 2026 buy was Dianthus Therapeutics: 836,000 shares worth $70.2M.
  • Farallon Capital Management added most to Electronic Arts in Q1 2026, an estimated $492M increase.
  • Farallon Capital Management's biggest Q1 2026 reduction was Wabtec, cutting an estimated $210M.
  • Farallon Capital Management fully exited Exact Sciences in Q1 2026, selling an estimated $650M.
  • Farallon Capital Management's ten largest holdings make up 50% of its $19.1B portfolio in Q1 2026.
  • Farallon Capital Management opened 48 new positions and closed 31 in Q1 2026.
  • Farallon Capital Management's portfolio value fell 17% quarter-over-quarter to $19.1B.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.